Appendix 4: Mean EQ 5D by EDSS state (baseline, and at 6/12/18 and 24 months) – pooled CARE MS I and II study results

Table Appendix 4.1: Mean EQ 5D by EDSS (baseline, and at 6/12/18 and 24 months) – pooled CARE MS I and II study results (alemtuzumab arm)

		0-0.5	1-1.5	2-2.5	3-3.5	4-4.5	5-5.5	6-6.5	7-7.5	8-8.5	9-9.5
0	mean	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	n	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
6	mean	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	n	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
12	mean	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	n	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
18	mean	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	n	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
24	mean	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
	n	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

Table Appendix 4.2: Mean EQ 5D change from baseline by EDSS (at 6/12/18 and 24 months) – pooled CARE MS I and II study results (alemtuzumab arm)

	0-0.5	1-1.5	2-2.5	3-3.5	4-4.5	5-5.5	6-6.5	7-7.5	8-8.5	9-9.5
6	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]			
12	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]			
18	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]			
24	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]			

Table Appendix 4.3: Mean EQ 5D by EDSS (baseline, and at 6/12/18 and 24 months) – pooled CARE MS I and II study results (Rebif 44 arm)

		0-0.5	1-1.5	2-2.5	3-3.5	4-4.5	5-5.5	6-6.5	7-7.5	8-8.5	9-9.5
0	mean	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]			
	n	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	0	0	
6	mean	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]		
	n	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]		
12	mean	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]		
	n	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]		
18	mean	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]			
	n	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]		
24	mean	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]		
	n	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	0	

Table Appendix 4.$: Mean EQ 5D change from baseline by EDSS (at 6/12/18 and 24 months) – pooled CARE MS I and II study results (Rebif 44 arm)

	0-0.5	1-1.5	2-2.5	3-3.5	4-4.5	5-5.5	6-6.5	7-7.5	8-8.5	9-9.5
6	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]			
12	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]			
18	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]			
24	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]			